Biological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. BI specialises in serum-free, xeno-free, animal component-free media, as well as contract manufacturing services that range from raw material supply, through labeling and packaging, to ready-to-market product.
A global CMO for medical media
BackgroundBiological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. BI specialises in serum-free, xeno-free, animal component-free media, as well as contract manufacturing services that range from raw material supply, through labeling and packaging, to ready-to-market product.
Switch for osteoporosis and obesity
Latest NewsGerman researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
Roche presents biomarker test to identify NSCLC responders to Tecentriq
Latest NewsResearchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker Tecentriq earlier than to FMI’s tissue based tumour mutation burden (TMB) assay.
Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis
Latest NewsGerman pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement therapies compensating for mutations that lead to cystic fibrosis.
Cellectis Appoints Stefan Scherer
AppointmentsCellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Arix Bioscience acquires 11% stake in Phamaxis Ltd.
Latest NewsAn investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.
Getting ready for Brexit
Latest NewsAs UK’s departure from the EU is fast approaching, stakeholders are preparing for the disruption a hard Brexit might cause. While EMA is scaling back activities, pharma companies are stockpiling meds.
Nanobots: Fiction becoming reality
BackgroundOnce confined to speculative and science fiction, miniature micro- or nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles – visualising the tiny machines inside the body, and preventing a potential immune response.
Cell Medica Appoints New CEO
AppointmentsCell Medica, a company active in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director.
ReViral raises US$55m
Latest NewsAntiviral drug discovery company ReViral announced the successful completion of a of a US$55m Series B financing. The funding will go toward clinical studies for its respiratory tract infection treatment.